The scope of this thematic journal contribution will entail next generation techniques to more precisely target immunosuppressive agents to organs or tailored to the patient themselves. These will include but not be limited to: nanotherapeutics, gene editing technologies, immuno-metabolic targeting, and or patient/organ-specific immunotherapies for transplantation.
Preservation and alloimmune injury are unavoidable events in organ transplantation after an allograft is implanted. In fact, these injuries can be exacerbated by the current standard of care methodologies and medications employed in organ transplantation. However, there is a growing trend amongst transplant scientist to develop precision based preservation and therapeutics in order to mitigate the injuries incurred pre-, peri- and post- transplant. The focus of this proposal is centered around targeted (bioengineered or otherwise) strategies to specifically condition organs or recipient cell subsets making them less immunogenic and resistant to ischemia reperfusion.
We are interested in original articles and perspective pieces that focus on next generation technologies that allow for more precise and patient/organ specific methodologies which can increase the utilization of marginal organs and minimize the use of immunosuppression leading to longer term patient and graft survival.
The scope of this thematic journal contribution will entail next generation techniques to more precisely target immunosuppressive agents to organs or tailored to the patient themselves. These will include but not be limited to: nanotherapeutics, gene editing technologies, immuno-metabolic targeting, and or patient/organ-specific immunotherapies for transplantation.
Preservation and alloimmune injury are unavoidable events in organ transplantation after an allograft is implanted. In fact, these injuries can be exacerbated by the current standard of care methodologies and medications employed in organ transplantation. However, there is a growing trend amongst transplant scientist to develop precision based preservation and therapeutics in order to mitigate the injuries incurred pre-, peri- and post- transplant. The focus of this proposal is centered around targeted (bioengineered or otherwise) strategies to specifically condition organs or recipient cell subsets making them less immunogenic and resistant to ischemia reperfusion.
We are interested in original articles and perspective pieces that focus on next generation technologies that allow for more precise and patient/organ specific methodologies which can increase the utilization of marginal organs and minimize the use of immunosuppression leading to longer term patient and graft survival.
